Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DU145 |
Human prostate cancer cell line, derived from metastatic site: brain | ATCC HTB-81 | Human | brain | cell line | adherent | plasmid | Metafectene | publication | S.-B. Varda et al., 2012, EP 2 371 846 | Link | ||
ECV-304 |
Human uroepithelial bladder carcinoma cell line | DSM ACC 310 | Human | urinary system | cell line | adherent | plasmid | Metafectene | publication | J. Pelisek et al., J Mol Med (Berl), Nov 2002; 80(11): 724-36 | |||
EFO-27 |
Human ovary adenocarcinoma cell line (cisplatin resistant) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | S. Dilruba et al., Cells, 2020, 9: 515, doi:10.3390/cells9020515 | Link | |||
EL-4 |
Mouse lymphoma T cell line | ATCC TIB-39 | Mouse | immune system | cell line | suspension | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | publication | K. Ohl et al., Frontiers in Immunology, 2016, 7:618, doi: 10.3389/fimmu.2016.00618 | Link | |
EL-4 |
Mouse T lymphoma cell line | ATCC TIB-39 | Mouse | immune system | cell line | suspension | plasmid | Metafectene | publication | A. Sahoo et al., J. Biol. Chem., Oct 2008; 283: 28860 - 28872 | Link | ||
ES-D3 |
Mouse pluripotent embryonic stem cell line | ATCC CRL-1934 | Mouse | unknown | stem cell | adherent | plasmid | Metafectene PRO | publication | M. Franek et al., Journal of Histochemistry & Cytochemistry, Nov 2016, 64, 669 - 686 | |||
ES-D3 [D3] |
Mouse embryonic multipotent stem cell | ATCC CRL-1934 | Mouse | unknown | stem cell | adherent | plasmid | Metafectene PRO | publication | J. Suchánková et al., Europ. J. of Histochemistry, 2014; 58:2389, doi:10.4081/ejh.2014.2389 | Link | ||
ESC |
Murine ESCs of the line R1 | Murine | unknown | stem cell | adherent | plasmid | stable transfection | Metafectene | publication | A. K. Shakhbazyan et al., Russian J. of Developmental Biol., 2013, 44 (6): 302–306, DOI: 10.1134/S1062360413060088 | |||
F-IPF |
Human primary lung fibroblasts | Human | respiratory system | primary cell | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene EASY | publication | X. Deng et al., The Int. J. of Biochem. & Cell Biol., 213, 45: 1366– 1376, doi.org/10.1016/j.biocel.2013.04.003 | |||
F-NL |
Human primary lung fibroblasts | Human | respiratory system | primary cell | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene EASY | publication | X. Deng et al., The Int. J. of Biochem. & Cell Biol., 213, 45: 1366– 1376, doi.org/10.1016/j.biocel.2013.04.003 | |||
F26IIB |
Human cells derived from a dyskeratosis congenita patient | Human | unknown | unknown | plasmid | K2 Transfection System | publication | L. Iarriccio et al., PLOS ONE, 2015, DOI:10.1371/journal.pone.0142980 | Link | ||||
F9 |
Mouse testis embryonal carcinoma cell line | ATCC CRL-1720 | Mouse | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | publication | L. Iarriccio et al., PLOS ONE, 2015, DOI:10.1371/journal.pone.0142980 | Link | |
F9-A353V |
Mouse testis embryonal carcinoma cell line (dyskerin-mutated) | Mouse | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | publication | L. Iarriccio et al., PLOS ONE, 2015, DOI:10.1371/journal.pone.0142980 | Link | ||
FG |
Human pancreatic adenocarcinoma cell line (Derivat of Colo357) | Human | digestive organs | cell line | adherent | plasmid | Metafectene | publication | H. Seeliger et al., Mol. Cancer Res., Feb 2009; 7: 189 - 198 | Link | |||
Flp-In 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S. M. Hoser et al., Genome Biology, 2020, 21: 299, doi.org/10.1186/s13059-020-02199-6 | Link | ||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Birk et al., J. Cell Sci., Apr 2013; 126: 1604 - 1617 | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | B.K. Shrestha et al., J Biol Chem., 2020, 295(5): 1240–1260, doi: 10.1074/jbc.RA119.010068 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | T. Ramming, Dissertation, 2014, Universitaet Basel | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | T. Ramming et al., Redox Biology, 2016, 714-20; doi.org/10.1016/j.redox.2015.11.004 | ||||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Wright et al., J. Biol. Chem., Oct 2013; 288: 31010 - 31018 | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | B. K. Shrestha et al., J. Biol. Chem., 2019,doi/10.1074/jbc.RA119.010068 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | B.K. Shrestha et al., J Biol Chem., 2020, 295(5): 1240–1260, doi: 10.1074/jbc.RA119.010068 | Link |